Astellas Pharma (OTCMKTS:ALPMY) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell?

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s stock price crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $10.83 and traded as low as $9.50. Astellas Pharma shares last traded at $9.67, with a volume of 96,545 shares changing hands.

Astellas Pharma Stock Performance

The company’s fifty day simple moving average is $9.61 and its 200 day simple moving average is $10.82. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $17.61 billion, a P/E ratio of -44.23 and a beta of 0.34.

Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earnings results on Tuesday, February 4th. The company reported $0.30 EPS for the quarter. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.69%. As a group, sell-side analysts forecast that Astellas Pharma Inc. will post 0.42 earnings per share for the current fiscal year.

About Astellas Pharma

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.